Report Categories
View AllRecent Articles
View All
Sangamo Therapeutics SGMO Stock Momentum Analysis Sangamo Therapeutics posts 797 downside EPS miss
IMUX Immunic tops Q4 2025 EPS estimates by 271 percent shares edge 031 percent higher
Is it a good time to enter Northern NTIC stock Northern logs 51 EPS miss below Street estimates
OSRH OSR Holdings sheds 88 as wider than expected Q4 2025 EPS miss sparks investor selloff